Mylan Inc.
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1961-01-01
- Employees
- 35K
- Market Cap
- -
- Website
- https://www.mylan.com/
REVIparin-BRIDging-in a General Practice Setting in GErmany
- Conditions
- First Posted Date
- 2015-10-19
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Mylan Inc.
- Target Recruit Count
- 77
- Registration Number
- NCT02579122
- Locations
- 🇩🇪
Research facility 136, Essen, Germany
🇩🇪Research facility 139, Gladbeck, Germany
🇩🇪Research facility 70, Nossen, Germany
Pharmacokinetics of TD-4208 in Patients With Severe Renal Impairment
- First Posted Date
- 2015-10-16
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- Mylan Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT02578082
- Locations
- 🇺🇸
Orlando Clinical Research Center (OCRC), Orlando, Florida, United States
A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2015-08-07
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- Mylan Inc.
- Target Recruit Count
- 1060
- Registration Number
- NCT02518139
- Locations
- 🇺🇸
Palmetto Medical Research Associates L.L.C, Easley, South Carolina, United States
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2015-07-31
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- Mylan Inc.
- Target Recruit Count
- 611
- Registration Number
- NCT02512510
- Locations
- 🇺🇸
Palmetto Medical Research Associates L.L.C., Easley, South Carolina, United States
Pharmacokinetic / Pharmacodynamic Study Comparing MYL-1401H, EU-sourced Neulasta and US-licensed Neulasta
- Conditions
- Interventions
- First Posted Date
- 2015-06-24
- Last Posted Date
- 2022-02-14
- Lead Sponsor
- Mylan Inc.
- Target Recruit Count
- 218
- Registration Number
- NCT02479646
- Locations
- 🇳🇱
PRA Health Sciences - Early Development Services, ZUidlaren, Netherlands
Study of Efficacy and Safety of Myl1401O + Taxane vs Herceptin©+ Taxane for 1st Line, Met. Br. Ca.
- Conditions
- Interventions
- First Posted Date
- 2015-06-16
- Last Posted Date
- 2022-02-14
- Lead Sponsor
- Mylan Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT02472964
- Locations
- 🇺🇦
Mylan Investigator Site, Uzhgorod, Ukraine
🇿🇦Mylan Investigational Site, Vereeniging, South Africa
Adalimumab PK Bioequivalence Study to EU and US Sourced Humira
- Conditions
- Interventions
- First Posted Date
- 2015-06-16
- Last Posted Date
- 2022-03-11
- Lead Sponsor
- Mylan Inc.
- Target Recruit Count
- 270
- Registration Number
- NCT02472912
- Locations
- 🇧🇪
SGS Belgium NV, Antwerp, Belgium
Phase I - Pharmacokinetic Comparability Study in Healthy Male Volunteers
- Conditions
- Interventions
- First Posted Date
- 2015-06-12
- Last Posted Date
- 2022-03-25
- Lead Sponsor
- Mylan Inc.
- Target Recruit Count
- 111
- Registration Number
- NCT02469987
- Locations
- 🇳🇱
PRA Health Sciences - Early Development Services, Zuidlaren, Netherlands
Efficacy and Safety Study With MYL-1401H and Neulasta
- Conditions
- Interventions
- First Posted Date
- 2015-06-10
- Last Posted Date
- 2022-02-14
- Lead Sponsor
- Mylan Inc.
- Target Recruit Count
- 193
- Registration Number
- NCT02467868
- Locations
- 🇧🇬
Mylan Investigational Site 3507, Plovdiv, Bulgaria
🇭🇺Mylan Investigational SIte 3606, Budapest, Hungary
🇭🇺Mylan Investigational Site 3607, Budapest, Hungary
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2015-06-01
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- Mylan Inc.
- Target Recruit Count
- 619
- Registration Number
- NCT02459080
- Locations
- 🇺🇸
Allergy Associates Research Center (AARC), Portland, Oregon, United States